Objectives: A panel composed of three immunomarkers, cytokeratin 19, HBME-1 and galectin-3, is recommended for improving the accuracy of diagnosing papillary thyroid carcinoma (PTC), but the results are sometimes inconsistent and difficult to interpret. We used immunocytochemistry to assess the utility of chemokine CXC ligand 12 (CXCL12) as a novel diagnostic marker for PTC employing paraffin-embedded cell blocks. Methods: We analyzed the expression of CXCL12 using immunocytochemical staining in 82 cases of thyroid lesions (47 PTCs and 35 thyroid lesions other than PTC). To determine the optimal cut-off value for the assessment of CXCL12 positivity, we used receiver operating characteristics (ROC). Results: ROC curves showed that the optimum diagnostic cut-off was 10% (area under the curve 0.950, 95% confidence interval 0.891-1.008), with exclusive CXCL12 expression in PTC compared to other thyroid lesions (p < 0.001). In total, more than 90% of the PTCs were associated with CXCL12 immunohistochemical staining, while only up to 11.4% of thyroid lesions other than PTC were positive for CXCL12. The follicular variant PTC showed 90% CXCL12 expression compared to 10.5% positivity in follicular neoplasm. Conclusion: Our findings indicate that CXCL12 may be an effective supplementary diagnostic marker for PTC in preoperative fine-needle aspiration cytology using the cell block method.

Keywords:
Chemokine CXC ligand 12, Immunocytochemistry, Papillary thyroid carcinoma, Cell blocks, Fine-needle aspiration
1.
Finley DJ, Arora N, Zhu B, Gallagher L, Fahey TJ 3rd: Molecular profiling distinguishes papillary carcinoma from benign thyroid nodules. J Clin Endocrinol Metab 2004;89:3214-3223.
2.
Mazzaferri EL: Management of a solitary thyroid nodule. N Engl J Med 1993;328:553-559.
3.
Cibas ES, Ali SZ: The Bethesda System for Reporting Thyroid Cytopathology. Am J Clin Pathol 2009;132:658-665.
4.
Baloch ZW, Gupta PK, Yu GH, Sack MJ, LiVolsi VA: Follicular variant of papillary carcinoma. Cytologic and histologic correlation. Am J Clin Pathol 1999;111:216-222.
5.
Fulciniti F, Benincasa G, Vetrani A, Palombini L: Follicular variant of papillary carcinoma: cytologic findings on FNAB samples - experience with 16 cases. Diagn Cytopathol 2001;25:86-93.
6.
Jung CK, Lee A, Jung ES, Choi YJ, Jung SL, Lee KY: Split sample comparison of a liquid-based method and conventional smears in thyroid fine needle aspiration. Acta Cytol 2008;52:313-319.
7.
Ljung BM: Thyroid fine-needle aspiration: smears versus liquid-based preparations. Cancer 2008;114:144-148.
8.
Afify AM, Liu J, Al-Khafaji BM: Cytologic artifacts and pitfalls of thyroid fine-needle aspiration using ThinPrep: a comparative retrospective review. Cancer 2001;93:179-186.
9.
Matos LL, Del Giglio AB, Matsubayashi CO, Farah ML, Del Giglio A, Pinhal MA: Expression of CK-19, galectin-3 and HBME-1 in the differentiation of thyroid lesions: systematic review and diagnostic meta-analysis. Diagn Pathol 2012;7:97.
10.
Nga ME, Lim GS, Soh CH, Kumarasinghe MP: HBME-1 and CK19 are highly discriminatory in the cytological diagnosis of papillary thyroid carcinoma. Diagn Cytopathol 2008;36:550-556.
11.
Schmitt AC, Cohen C, Siddiqui MT: Paired box gene 8, HBME-1, and cytokeratin 19 expression in preoperative fine-needle aspiration of papillary thyroid carcinoma: diagnostic utility. Cancer Cytopathol 2010;118:196-202.
12.
Bonzanini M, Amadori PL, Sagramoso C, Dalla Palma P: Expression of cytokeratin 19 and protein p63 in fine needle aspiration biopsy of papillary thyroid carcinoma. Acta Cytol 2008;52:541-548.
13.
Saggiorato E, De Pompa R, Volante M, Cappia S, Arecco F, Dei Tos AP, Orlandi F, Papotti M: Characterization of thyroid ‘follicular neoplasms' in fine-needle aspiration cytological specimens using a panel of immunohistochemical markers: a proposal for clinical application. Endocr Relat Cancer 2005;12:305-317.
14.
Bartolazzi A, Gasbarri A, Papotti M, Bussolati G, Lucante T, Khan A, Inohara H, Marandino F, Orlandi F, Nardi F, Vecchione A, Tecce R, Larsson O: Application of an immunodiagnostic method for improving preoperative diagnosis of nodular thyroid lesions. Lancet 2001;357:1644-1650.
15.
Herrmann ME, LiVolsi VA, Pasha TL, Roberts SA, Wojcik EM, Baloch ZW: Immunohistochemical expression of galectin-3 in benign and malignant thyroid lesions. Arch Pathol Lab Med 2002;126:710-713.
16.
Asioli S, Maletta F, Pacchioni D, Lupo R, Bussolati G: Cytological detection of papillary thyroid carcinomas by nuclear membrane decoration with emerin staining. Virchows Arch 2010;457:43-51.
17.
Teicher BA, Fricker SP: CXCL12 (SDF-1)/CXCR4 pathway in cancer. Clin Cancer Res 2010;16:2927-2931.
18.
Michael CW, Pang Y, Pu RT, Hasteh F, Griffith KA: Cellular adequacy for thyroid aspirates prepared by ThinPrep: how many cells are needed? Diagn Cytopathol 2007;35:792-797.
19.
DeLellis R, Young R, Sobin L: Tumours of the thyroid and parathyroid; in DeLellis RA, Lloyd RV, Heitz PU, Eng C (eds): WHO Classification of Tumours: Pathology and Genetics Of tumors of the Endocrine Organs. Lyon, IARC, 2004, pp 51-103.
20.
Boerner SL, Asa SL (eds): Biopsy Interpretation of the Thyroid. Philadelphia, Lippincott, Williams and Wilkins, 2010.
21.
Bongiovanni M, Spitale A, Faquin WC, Mazzucchelli L, Baloch ZW: The Bethesda System for Reporting Thyroid Cytopathology: a meta-analysis. Acta Cytol 2012;56:333-339.
22.
Theoharis CG, Schofield KM, Hammers L, Udelsman R, Chhieng DC: The Bethesda thyroid fine-needle aspiration classification system: year 1 at an academic institution. Thyroid 2009;19:1215-1223.
23.
Bohacek L, Milas M, Mitchell J, Siperstein A, Berber E: Diagnostic accuracy of surgeon-performed ultrasound-guided fine-needle aspiration of thyroid nodules. Ann Surg Oncol 2012;19:45-51.
24.
Ryu HS, Park do J, Kim HH, Kim WH, Lee HS: Combination of epithelial-mesenchymal transition and cancer stem cell-like phenotypes has independent prognostic value in gastric cancer. Hum Pathol 2012;43:520-528.
25.
Liu Z, Sun DX, Teng XY, Xu WX, Meng XP, Wang BS: Expression of stromal cell-derived factor 1 and CXCR7 in papillary thyroid carcinoma. Endocr Pathol 2012;23:247-253.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.